Evidence map›Paper›PMID 35927247›Full record

ArticleBlood cancer journal2022

Venetoclax ex vivo functional profiling predicts improved progression-free survival.

Vikas A Gupta, Shannon M Matulis, Benjamin G Barwick, R Devin Bog, Conrad W Shebelut, Mala Shanmugam, Paola Neri, Nizar J Bahlis, Madhav V Dhodapkar, Leonard T Heffner and 7 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Vikas A GuptaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA. vikas.gupta@emory.edu.ORCID 0000-0002-8980-2338
Shannon M MatulisDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Benjamin G BarwickDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0001-9810-3566
R Devin BogDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Conrad W ShebelutDepartment of Pathology and Laboratory Medicine, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Mala ShanmugamDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-4415-8083
Paola NeriArnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
Nizar J BahlisArnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, AB, Canada.
Madhav V DhodapkarDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-8249-5988
Leonard T HeffnerDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Craig C HofmeisterDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-4816-1607
Nisha S JosephDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Sagar LonialDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-8322-9323
Jonathan L KaufmanDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0002-5687-6429
David L JayeDepartment of Pathology and Laboratory Medicine, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.
Ajay K NookaDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA.ORCID 0000-0003-4165-6869
Lawrence H BoiseDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Emory University School of Medicine, Atlanta, GA, USA. lboise@emory.edu.ORCID 0000-0001-9436-8815

Funding

Winship Cancer Institute Cancer Center Support GrantP30CA138292 · NCI · EMORY UNIVERSITY · PI Suresh S Ramalingam · 2009 to 2026
$47.5M
The Role of CD86 in Multiple MyelomaR01CA192844 · NCI · EMORY UNIVERSITY · PI BOISE, LAWRENCE H. · 2016 to 2020
$1.9M
NCI NIH HHS P30 CA138292NCI NIH HHS R01 CA192844
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Bridged Bicyclo Compounds, HeterocyclicSulfonamidesAntineoplastic Combined Chemotherapy ProtocolsHumansProgression-Free SurvivalProto-Oncogene Proteins c-bcl-2Bridged Bicyclo Compounds, HeterocyclicProto-Oncogene Proteins c-bcl-2Sulfonamidesvenetoclax

Identifiers

PMID35927247
PMCPMC9352682

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.